Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 3/2010

01-06-2010

Theories of the Pathogenesis of Inclusion Body Myositis

Author: Steven A. Greenberg

Published in: Current Rheumatology Reports | Issue 3/2010

Login to get access

Abstract

Inclusion body myositis is a progressive disease of the skeletal muscle. Here, specific theories of its pathogenesis are reviewed and general considerations pertaining to modeling of this disease discussed. Understanding of inclusion body myositis disease mechanism remains extremely poor. Current published animal models do not represent the disease. Future studies need to consider the critical role of biomarkers and methodologic issues in their discovery.
Literature
1.
Yunis EJ, Samaha FJ: Inclusion body myositis. Lab Invest 1971, 25:240–248.PubMed
2.
• Machado P, Miller A, Holton J, Hanna M: Sporadic inclusion body myositis: an unsolved mystery. Acta Reumatol Port 2009, 34:161–182. This is a comprehensive review of many aspects of IBM. PubMed
3.
Karpati G, O’Ferrall EK: Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol 2009, 65:7–11.CrossRefPubMed
4.
Greenberg SA: Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009, 9:83–89.CrossRefPubMed
5.
Askanas V, Engel WK, Nogalska A: Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19:493–506.CrossRefPubMed
6.
• Needham M, Mastaglia FL: Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008, 18:6–16. This is a thoughtful review of IBM mechanistic theories.CrossRefPubMed
7.
• Greenberg SA: Inflammatory myopathies: disease mechanisms. Curr Opin Neurol 2009, 22:516–523. This is a review of inflammatory myopathy disease mechanisms that focuses on dermatomyositis and IBM.CrossRefPubMed
8.
Askanas V, Engel WK: Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66(2 Suppl 1):S39–S48.PubMed
9.
• Greenberg SA: How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009, 339:b2680. This article rigorously demonstrates how distortions in the scholarly process of citation may create belief in unfounded claims, with particular attention paid to claims regarding Aβ in IBM.CrossRefPubMed
10.
Muth IE, Barthel K, Bahr M, et al.: Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009, 80:1344–1349.CrossRefPubMed
11.
Greenberg SA: Comment on ‘Interrelation of inflammation and APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid in skeletal muscle.’ Brain 2009, 132:e106.CrossRefPubMed
12.
Askanas V, Sarkozi E, Bilak M, et al.: Human muscle macrophages express beta-amyloid precursor and prion proteins and their mRNAs. Neuroreport 1995, 6:1045–1049.CrossRefPubMed
13.
Sarkozi E, Askanas V, Johnson SA, et al.: Expression of beta-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro. Exp Neurol 1994, 128:27–33.CrossRefPubMed
14.
Sarkozi E, Askanas V, Johnson SA, et al.: beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993, 4:815–818.CrossRefPubMed
15.
Nalbantoglu J, Karpati G, Carpenter S: Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994, 144:874–882.PubMed
16.
Greenberg SA, Sanoudou D, Haslett JN, et al.: Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170–1182.PubMed
17.
Schmidt J, Barthel K, Wrede A, et al.: Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228–1240.CrossRefPubMed
18.
Fukuchi K, Pham D, Hart M, et al.: Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy. Am J Pathol 1998, 153:1687–1693.PubMed
19.
Jin LW, Hearn MG, Ogburn CE, et al.: Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol 1998, 153:1679–1686.PubMed
20.
Sugarman MC, Yamasaki TR, Oddo S, et al.: Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002, 99:6334–6339.CrossRefPubMed
21.
Strazielle C, Dumont M, Fukuchi K, Lalonde R: Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on cytochrome oxidase activity in skeletal muscle and brain. J Chem Neuroanat 2004, 27:237–246.CrossRefPubMed
22.
Kitazawa M, Green KN, Caccamo A, LaFerla FM: Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol 2006, 168:1986–1997.CrossRefPubMed
23.
Moussa CE, Fu Q, Kumar P, et al.: Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. FASEB J 2006, 20:2165–2167.CrossRefPubMed
24.
Sugarman MC, Kitazawa M, Baker M, et al.: Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging 2006, 27:423–432.CrossRefPubMed
25.
Kitazawa M, Trinh DN, LaFerla FM: Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008, 64:15–24.CrossRefPubMed
26.
Rebolledo DL, Minniti AN, Grez PM, et al.: Inclusion body myositis: a view from the Caenorhabditis elegans muscle. Mol Neurobiol 2008, 38:178–198.CrossRefPubMed
27.
• Salajegheh M, Pinkus JL, Nazareno R, et al.: Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009, 40:520–528. The identity of SMI-31 immunoreactive material widely interpreted as phosphorylated tau was shown to likely be neurofilament H.CrossRefPubMed
28.
Maurage CA, Bussière T, Sergeant N, et al.: Tau aggregates are abnormally phosphorylated in inclusion body myositis and have an immunoelectrophoretic profile distinct from other tauopathies. Neuropathol Appl Neurobiol 2004, 30:624–634.CrossRefPubMed
29.
Delaunay A, Bromberg KD, Hayashi Y, et al.: The ER-bound RING finger protein 5 (RNF5/RMA1) causes degenerative myopathy in transgenic mice and is deregulated in inclusion body myositis. PLoS ONE 2008, 3:e1609.CrossRefPubMed
30.
Greenberg SA: Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008–2019.CrossRefPubMed
31.
Engel AG, Arahata K: Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209–215.CrossRefPubMed
32.
Greenberg SA, Bradshaw EM, Pinkus JL, et al.: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65:1782–1787. (Published erratum appears in Neurology 2006, 66:493.)CrossRefPubMed
33.
• Bradshaw EM, Orihuela A, McArdel SL, et al.: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547–556. The intramuscular B-cell response in IBM was shown to be antigen driven, laying the groundwork for future antibody-based antigen discovery.PubMed
34.
Salajegheh M, Lin YY, Parker KC, et al.: Using humoral immunity for the identification of candidate antigens in inclusion body myositis [abstract]. Neurology 2007, 68(Suppl 1):A361.
35.
Banwell BL, Engel AG: AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000, 54:1033–1041.PubMed
36.
Chou SM: Myxovirus-like structures in a case of human chronic polymyositis. Science 1967, 158:1453–1455.CrossRefPubMed
37.
Chou SM: Myxovirus-like structures and accompanying nuclear changes in chronic polymyositis. Arch Pathol 1968, 86:649–658.PubMed
38.
Carpenter S, Karpati G, Heller I, Eisen A: Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978, 28:8–17.PubMed
39.
40.
Karpati G, Carpenter S: Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993, 2:527–556.PubMed
41.
Greenberg SA, Pinkus JL, Amato AA: Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006, 34:406–416.CrossRefPubMed
42.
• Weihl CC, Temiz P, Miller SE, et al.: TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008, 79:1186–1189. This article found sarcoplasmic TDP-43, a protein normally seen only in nuclei, in biopsy samples from patients with IBM and valosin-containing protein mutation inclusion body myopathies.CrossRefPubMed
43.
•• Salajegheh M, Pinkus JL, Taylor JP, et al.: Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009, 40:19–31. TDP-43 presence in IBM was quantitated in relation to other reported biomarkers. The relation between this nucleic acid-binding protein and nuclear abnormalities is discussed.CrossRefPubMed
44.
Küsters B, van Hoeve BJ, Schelhaas HJ, et al.: TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009, 117:209–211.CrossRefPubMed
45.
Olivé M, Janué A, Moreno D, et al.: TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009, 68:262–273.CrossRefPubMed
46.
Capsoni S, Ruberti F, Di Daniel E, Cattaneo A: Muscular dystrophy in adult and aged anti-NGF transgenic mice resembles an inclusion body myopathy. J Neurosci Res 2000, 59:553–560.CrossRefPubMed
47.
Chen X, Ghribi O, Geiger JD: Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. Am J Physiol Regul Integr Comp Physiol 2008, 294:R829–R835.PubMed
48.
Kitazawa M, Vasilevko V, Cribbs DH, LaFerla FM: Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model. J Neurosci 2009, 29:6132–6141.CrossRefPubMed
49.
Koistinen H, Prinjha R, Soden P, et al.: Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. Muscle Nerve 2006, 34:444–450.CrossRefPubMed
50.
Yang CC, Alvarez RB, Engel WK, Askanas V: Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 1996, 8:153–158.CrossRefPubMed
Metadata
Title
Theories of the Pathogenesis of Inclusion Body Myositis
Author
Steven A. Greenberg
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0102-5

Other articles of this Issue 3/2010

Current Rheumatology Reports 3/2010 Go to the issue

ReviewPaper

The Societal Burden of Osteoporosis

ReviewPaper

Dermatomyositis and Type 1 Interferons

ReviewPaper

Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy

ReviewPaper

Mechanical Factors and Bone Health: Effects of Weightlessness and Neurologic Injury

ReviewPaper

Drug-related Myopathies of Which the Clinician Should Be Aware

ReviewPaper

Cutaneous Manifestations of Dermatomyositis and Their Management
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits